ANGPTL4, a key regulator of triglyceride clearance via lipoprotein lipase inhibition, is an emerging therapeutic target for hypertriglyceridemia and has been implicated in colorectal tumourigenesis in in vitro and in vivo studies.56–59 Though further functional and experimental validation is required, our genetic findings tentatively support the pharmacological inhibition of ANGPTL4 as a potential strategy for the dual prevention of CAD and colorectal cancer. This evidence concerns the gene LPL and coronary artery disorder.